BioCentury
ARTICLE | Clinical News

ATH008: Phase IIb started

April 25, 2011 7:00 AM UTC

Advancell began a double-blind, placebo-controlled, European Phase IIb trial to evaluate twice-daily 1%, 3% and 8% ATH008 in up to 100 patients with PPES secondary to capecitabine monotherapy. Roche ...